Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. reports a 72% reduction in depression severity among patients six months after using their lead drug, MB22001, in clinical trials. The company is pioneering the use of microdoses of psychedelic medicines for take-home use, aiming to transform the treatment of depressive disorders.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
